New Two-Pronged attack on rare 'Jelly Belly' cancer
NCT ID NCT07341360
Summary
This early-phase study is testing a new two-part treatment for a rare abdominal cancer called pseudomyxoma peritonei (PMP). It combines a personalized vaccine designed to target a specific mutation in the cancer with a drug (tislelizumab) that helps the immune system fight tumors. The main goals are to see if the treatment is safe and if it can trigger a strong immune response against the cancer in up to 10 patients whose disease has returned or cannot be surgically removed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSEUDOMYXOMA PERITONEI are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Oslo University Hospital HF, Radium
RECRUITINGOslo, Oslo County, 0379, Norway
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.